Ali Behbahani - Oct 21, 2021 Form 3 Insider Report for MINERVA SURGICAL INC (UTRS)

Role
Director
Signature
/s/ Sasha Keough, attorney in fact
Stock symbol
UTRS
Transactions as of
Oct 21, 2021
Transactions value $
$0
Form type
3
Date filed
10/21/2021, 08:02 PM
Previous filing
Oct 19, 2021
Next filing
Oct 28, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding UTRS Series B Preferred Stock Oct 21, 2021 Common Stock 281 Direct F1
holding UTRS Series C Preferred Stock Oct 21, 2021 Common Stock 704 Direct F1
holding UTRS Series D Preferred Stock Oct 21, 2021 Common Stock 4.2K Direct F1
holding UTRS Subordinated Secured Convertible Promissory Note Oct 21, 2021 Series D Preferred Stock Direct F2
holding UTRS Subordinated Secured Convertible Promissory Note Oct 21, 2021 Series D Preferred Stock Direct F3
holding UTRS Subordinated Secured Convertible Promissory Note Oct 21, 2021 Series D Preferred Stock Direct F4
holding UTRS Subordinated Secured Convertible Promissory Note Oct 21, 2021 Series D Preferred Stock Direct F5
holding UTRS Subordinated Secured Convertible Promissory Note Oct 21, 2021 Series D Preferred Stock Direct F6
holding UTRS Subordinated Secured Convertible Promissory Note Oct 21, 2021 Series D Preferred Stock Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock (collectively, the "Preferred Stock") is convertible into shares of the Issuer's common stock ("Common Stock") at a 1:1 ratio in connection with the Company's initial public offering. The Preferred Stock has no expiration date.
F2 Represents $6,155.15 of outstanding principal and interest calculated through October 26, 2021, at which time it is expected that this amount shall convert into shares of Series D Preferred Stock at a conversion price per share of approximately $11.31, which shares will then convert into shares of Common Stock at a 1:1 ratio in connection with the Company's initial public offering.
F3 Represents $5,920.31 of outstanding principal and interest calculated through October 26, 2021, at which time it is expected that this amount shall convert into shares of Series D Preferred Stock at a conversion price per share of approximately $11.31, which shares will then convert into shares of Common Stock at a 1:1 ratio in connection with the Company's initial public offering.
F4 Represents $5,837.08 of outstanding principal and interest calculated through October 26, 2021, at which time it is expected that this amount shall convert into shares of Series D Preferred Stock at a conversion price per share of approximately $11.31, which shares will then convert into shares of Common Stock at a 1:1 ratio in connection with the Company's initial public offering.
F5 Represents $5,674.16 of outstanding principal and interest calculated through October 26, 2021, at which time it is expected that this amount shall convert into shares of Series D Preferred Stock at a conversion price per share of approximately $11.31, which shares will then convert into shares of Common Stock at a 1:1 ratio in connection with the Company's initial public offering.
F6 Represents $5,436.88 of outstanding principal and interest calculated through October 26, 2021, at which time it is expected that this amount shall convert into shares of Series D Preferred Stock at a conversion price per share of approximately $11.31, which shares will then convert into shares of Common Stock at a 1:1 ratio in connection with the Company's initial public offering.
F7 Represents $8,398.26 of outstanding principal and interest calculated through October 26, 2021, at which time it is expected that this amount shall convert into shares of Series D Preferred Stock at a conversion price per share of approximately $11.31, which shares will then convert into shares of Common Stock at a 1:1 ratio in connection with the Company's initial public offering.